139 related articles for article (PubMed ID: 21793965)
1. Discovery and development of avotermin (recombinant human transforming growth factor beta 3): a new class of prophylactic therapeutic for the improvement of scarring.
Occleston NL; O'Kane S; Laverty HG; Cooper M; Fairlamb D; Mason T; Bush JA; Ferguson MW
Wound Repair Regen; 2011 Sep; 19 Suppl 1():s38-48. PubMed ID: 21793965
[TBL] [Abstract][Full Text] [Related]
2. Avotermin for the improvement of scar appearance: a new pharmaceutical in a new therapeutic area.
Occleston NL; Fairlamb D; Hutchison J; O'Kane S; Ferguson MW
Expert Opin Investig Drugs; 2009 Aug; 18(8):1231-9. PubMed ID: 19604123
[TBL] [Abstract][Full Text] [Related]
3. Scar-free healing: from embryonic mechanisms to adult therapeutic intervention.
Ferguson MW; O'Kane S
Philos Trans R Soc Lond B Biol Sci; 2004 May; 359(1445):839-50. PubMed ID: 15293811
[TBL] [Abstract][Full Text] [Related]
4. Avotermin: a novel antiscarring agent.
Durani P; Occleston N; O'Kane S; Ferguson MW
Int J Low Extrem Wounds; 2008 Sep; 7(3):160-8. PubMed ID: 18757391
[TBL] [Abstract][Full Text] [Related]
5. New therapeutics for the prevention and reduction of scarring.
Occleston NL; O'Kane S; Goldspink N; Ferguson MW
Drug Discov Today; 2008 Nov; 13(21-22):973-81. PubMed ID: 18824245
[TBL] [Abstract][Full Text] [Related]
6. Prevention and reduction of scarring in the skin by Transforming Growth Factor beta 3 (TGFbeta3): from laboratory discovery to clinical pharmaceutical.
Occleston NL; Laverty HG; O'Kane S; Ferguson MW
J Biomater Sci Polym Ed; 2008; 19(8):1047-63. PubMed ID: 18644230
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II clinical trial of avotermin versus placebo for scar improvement.
McCollum PT; Bush JA; James G; Mason T; O'Kane S; McCollum C; Krievins D; Shiralkar S; Ferguson MW
Br J Surg; 2011 Jul; 98(7):925-34. PubMed ID: 21618480
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies.
Ferguson MW; Duncan J; Bond J; Bush J; Durani P; So K; Taylor L; Chantrey J; Mason T; James G; Laverty H; Occleston NL; Sattar A; Ludlow A; O'Kane S
Lancet; 2009 Apr; 373(9671):1264-74. PubMed ID: 19362676
[TBL] [Abstract][Full Text] [Related]
9. Scar-improving efficacy of avotermin administered into the wound margins of skin incisions as evaluated by a randomized, double-blind, placebo-controlled, phase II clinical trial.
Bush J; Duncan JAL; Bond JS; Durani P; So K; Mason T; O'Kane S; Ferguson MWJ
Plast Reconstr Surg; 2010 Nov; 126(5):1604-1615. PubMed ID: 21042116
[TBL] [Abstract][Full Text] [Related]
10. Prevention of buccal mucosa scarring with transforming growth factor β3.
Ohno S; Hirano S; Kanemaru S; Tateya I; Kitani Y; Kojima T; Nakamura T; Ito J
Laryngoscope; 2011 Jul; 121(7):1404-9. PubMed ID: 21647892
[TBL] [Abstract][Full Text] [Related]
11. The temporal effects of anti-TGF-beta1, 2, and 3 monoclonal antibody on wound healing and hypertrophic scar formation.
Lu L; Saulis AS; Liu WR; Roy NK; Chao JD; Ledbetter S; Mustoe TA
J Am Coll Surg; 2005 Sep; 201(3):391-7. PubMed ID: 16125072
[TBL] [Abstract][Full Text] [Related]
12. Avotermin for scar improvement following scar revision surgery: a randomized, double-blind, within-patient, placebo-controlled, phase II clinical trial.
So K; McGrouther DA; Bush JA; Durani P; Taylor L; Skotny G; Mason T; Metcalfe A; O'Kane S; Ferguson MWJ
Plast Reconstr Surg; 2011 Jul; 128(1):163-172. PubMed ID: 21701333
[TBL] [Abstract][Full Text] [Related]
13. Novel therapies for scar reduction and regenerative healing of skin wounds.
Rhett JM; Ghatnekar GS; Palatinus JA; O'Quinn M; Yost MJ; Gourdie RG
Trends Biotechnol; 2008 Apr; 26(4):173-80. PubMed ID: 18295916
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-10 reduces scar formation in both animal and human cutaneous wounds: results of two preclinical and phase II randomized control studies.
Kieran I; Knock A; Bush J; So K; Metcalfe A; Hobson R; Mason T; O'Kane S; Ferguson M
Wound Repair Regen; 2013; 21(3):428-36. PubMed ID: 23627460
[TBL] [Abstract][Full Text] [Related]
15. [Beyond TGF-beta: wound healing modulation in filtering glaucoma surgery].
Meyer-Ter-Vehn T; Klink T; Grehn F; Schlunck G
Klin Monbl Augenheilkd; 2009 Jan; 226(1):22-6. PubMed ID: 19173159
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of the efficacy and tolerability of a unique topical scar product vs white petrolatum following shave biopsies.
Kircik LH
J Drugs Dermatol; 2013 Jan; 12(1):86-90. PubMed ID: 23377333
[TBL] [Abstract][Full Text] [Related]
17. A new approach for the prophylactic improvement of surgical scarring: avotermin (TGF beta 3).
Young VL; Bush J; O'Kane S
Clin Plast Surg; 2009 Apr; 36(2):307-13, viii. PubMed ID: 19309655
[TBL] [Abstract][Full Text] [Related]
18. The role of the fetal fibroblast and transforming growth factor-beta in a model of human fetal wound repair.
Lin RY; Adzick NS
Semin Pediatr Surg; 1996 Aug; 5(3):165-74. PubMed ID: 8858763
[TBL] [Abstract][Full Text] [Related]
19. Ontogeny of expression of transforming growth factor-beta and its receptors and their possible relationship with scarless healing in human fetal skin.
Chen W; Fu X; Ge S; Sun T; Zhou G; Jiang D; Sheng Z
Wound Repair Regen; 2005; 13(1):68-75. PubMed ID: 15659038
[TBL] [Abstract][Full Text] [Related]
20. Association of TGFβ1 and clinical factors with scar outcome following melanoma excision.
Ward SV; Cadby G; Heyworth JS; Fear MW; Wallace HJ; Cole JM; Wood FM; Palmer LJ
Arch Dermatol Res; 2012 Jul; 304(5):343-51. PubMed ID: 22566144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
